Most funding rounds sell a slice of a company. This one sold close to a third of it. Gate2Brain, a Barcelona biotech spun out of IRB Barcelona, the University of Barcelona and Hospital Sant Joan de Deu in 2020, has taken €7 million from Shilpa Biocare, a wholly owned subsidiary of the Indian pharmaceutical group Shilpa Medicare, in exchange for a 30.4% equity stake. It is the largest investment the company has raised, and it is shaped less like a venture round than like the first step of a relationship that usually ends in acquisition.

That structure is the most interesting thing about the deal, and it is worth sitting with before the science. A venture fund buys a minority position and waits for the next round to mark it up. A strategic pharmaceutical investor buying 30.4% of a preclinical biotech is doing something different: taking a board-level stake in the outcome, securing an inside track on the technology, and, in effect, pricing an option on the whole company. For a small European biotech, that trade can be the difference between reaching the clinic and stalling in the lab. It can also box in the cap table for whoever wants to invest next.

What the money is buying its way toward

The problem Gate2Brain works on is one of the oldest walls in neuroscience. The blood-brain barrier keeps most drugs out of the brain, which is precisely why brain tumours and central-nervous-system diseases remain so hard to treat: the medicine cannot reach the target. Gate2Brain’s answer is a proprietary peptide called MiniAp4, a molecular shuttle designed to ferry therapeutics across that barrier. Its lead candidate, G2B-002, is a first-in-class therapeutic for aggressive paediatric and adult brain tumours and has already received Orphan Drug Designation from both the US Food and Drug Administration and the European Medicines Agency, a signal that regulators see a genuine unmet need and a path worth easing.

Preclinical studies, by the company’s account, show improved delivery into the brain and reduced side effects in paediatric tumours. That is the hopeful part. The sober part is that it is still preclinical, and the history of blood-brain-barrier delivery is a graveyard of approaches that looked elegant in mice and never crossed into people. CEO and chief scientific officer Meritxell Teixido, a chemist with more than a decade in brain drug delivery, has built the company around the shuttle technology with chief operating officer Gloria Sanclimens; the platform is the asset, and G2B-002 is its first real test.

European biotech capital is, for the moment, willing to fund exactly this kind of early science. In the same stretch of weeks, a Paris company raised the largest biotech Series A in French history, part of a broader surge of money into the sector across the continent. Gate2Brain’s €7 million sits at the small end of that wave, but the shape of its raise says something the larger rounds do not: that a strategic manufacturer, not just a venture fund, now sees a Barcelona peptide platform as worth owning a piece of.

The strategic-investor trade, and its cost

What Shilpa brings is the unglamorous machinery that kills more biotechs than bad science does. Manufacturing a complex peptide therapeutic to clinical standard, developing the chemistry and controls a regulator will accept, and steering a candidate through the filing maze in multiple jurisdictions are all things a six-year-old company with a small team cannot easily do alone. Shilpa, which serves customers in more than 80 countries and specialises in oncology, biologics and complex formulations, can. For Gate2Brain, the partnership compresses years of capability-building into a single agreement.

The cost is concentration. A single corporate investor holding 30.4% and an inside track on the lead asset is a powerful ally and a complicated one. It can deter later venture investors who do not want to back a company with a strategic already positioned for first refusal, and it can quietly set the terms of any eventual takeout in the partner’s favour. The €7 million also values the company modestly for a platform with FDA and EMA orphan designations in hand, which is the trade a preclinical biotech makes when it chooses certainty of partnership over the higher price a competitive venture round might fetch.

The receipts on the science side are early but not thin. Gate2Brain has drawn support from Fundacion Botin, Banco Sabadell, the European Innovation Council’s Accelerator, Spain’s CDTI, ACCIO, and Fundacion la Caixa, the kind of public and quasi-public backing that European deep biotech leans on before private capital arrives in force. The orphan designations are real regulatory signals, not press-release flourishes. And the unmet need is genuine: aggressive paediatric brain tumours remain among the cruellest diagnoses in medicine, with few options that reach the tumour at all.

What the deal cannot settle is the only question that matters, which is whether MiniAp4 carries a drug across the barrier in a child and shrinks a tumour without harming the patient. €7 million and a manufacturing partner buy Gate2Brain the runway to find out, and hand a large pharmaceutical group a third of the upside if the answer is yes. The next clinical readout is where that bet either becomes a therapy or becomes a lesson, and for once the size of the cheque is the least telling part of the story.

Filed by eu-tailwind. Independent reporting on the rise of European tech.